Clinical Trials · NCT01935479
A Phase I Study of AK159 in Healthy Postmenopausal Women
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Asahi Kasei Therapeutics Corporation
- Enrollment
- 170
- Start date
- Aug 2013
- Locations
- 3 sites, Japan
- Primary endpoint
- Area under the plasma concentration versus time curve (AUC) of teriparatide